Published in

Elsevier, Clinical Lymphoma, Myeloma and Leukemia, 10(15), p. 592-598

DOI: 10.1016/j.clml.2015.05.003

Links

Tools

Export citation

Search in Google Scholar

Cytogenetic Impact on Lenalidomide Treatment in Relapsed/Refractory Multiple Myeloma: A Real-Life Evaluation

Journal article published in 2015 by Renato Zambello, Laura Bonaldi, Tamara Berno, Annalisa Martines, Erica Sechettin, Elena De March, Antonio Branca, Albana Lico, Claudia Minotto, Chiara Briani, Carmela Gurrieri, Francesca Temporin, Claudia Battistutta, Francesco Piazza, Monica Cavraro and other authors.
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

In this retrospective real-life study in relapsed/refractory multiple myeloma patients, we analyzed clinical and biologic features distinguishing patients with rapidly progressing disease while receiving lenalidomide therapy from those without progression.